1. Home
  2. ENVB vs VRAX Comparison

ENVB vs VRAX Comparison

Compare ENVB & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Enveric Biosciences Inc.

ENVB

Enveric Biosciences Inc.

HOLD

Current Price

$3.73

Market Cap

3.0M

Sector

Health Care

ML Signal

HOLD

Logo Virax Biolabs Group Limited

VRAX

Virax Biolabs Group Limited

HOLD

Current Price

$0.38

Market Cap

2.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ENVB
VRAX
Founded
1994
2013
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.0M
2.9M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
ENVB
VRAX
Price
$3.73
$0.38
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$120.00
$3.00
AVG Volume (30 Days)
1.9M
15.7M
Earning Date
11-14-2025
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$2,986.00
Revenue This Year
N/A
$217,274.83
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.60
$0.31
52 Week High
$96.30
$3.20

Technical Indicators

Market Signals
Indicator
ENVB
VRAX
Relative Strength Index (RSI) 40.00 40.69
Support Level $4.90 $0.31
Resistance Level $5.34 $0.43
Average True Range (ATR) 0.85 0.04
MACD -0.29 -0.01
Stochastic Oscillator 0.80 25.29

Price Performance

Historical Comparison
ENVB
VRAX

About ENVB Enveric Biosciences Inc.

Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.

About VRAX Virax Biolabs Group Limited

Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes (HSV-1) and Human Papillomavirus (HPV).

Share on Social Networks: